MDL-1 ligand
AssigneeMerck Sharp & Dohme Corp.
InventorsBarbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Joseph H. Phillips
Life of this patent
Estimating the term…
Abstract
The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
Claims5
A method of depleting a population of T lymphocyte cells comprising contacting the population of T lymphocyte cells with an MDL-1 fusion protein that binds directly or indirectly to a molecule expressed on the T lymphocyte cells wherein the MDL-1 fusion protein comprises an extracellular domain of MDL-1 and a heterologous protein which is an Fc portion of an immunoglobulin molecule.
Dependencies are inferred from the claim text.